SLSThe Q1 update: less Hollywood, more clinical suspense
SELLAS Life Sciences spent its Q1 2026 update reminding investors that biotech is basically a waiting room with a stock ticker. The company said its pivotal Phase 3 REGAL trial for galinpepimut-S, or GPS, in acute myeloid leukemia had reached 78 events as of May 11th, and the final analysis is expected after the 80th event. In plain English: the clock is almost done ticking, but SELLAS is still blinded to the outcome.
Why the event count matters
For a company like SELLAS, the trial event count is the whole ballgame. Once those last two events roll in, the company can move toward the final analysis on a study that could be a make-or-break moment for its lead program. If the data land well, investors may finally get the kind of catalyst biotech folks pin their hopes on. If not, well, biotech can turn into an expensive science fair real fast.
Cash buys time, and biotech loves time
SELLAS also said it ended March with $107.1 million in cash and cash equivalents, then picked up another $7.5 million in Q2 through warrant exercises. That matters because clinical development eats cash like a road trip eats gas station snacks. More runway means more room to keep advancing its Phase 2 SLS009 program in newly diagnosed first-line AML while it waits on the REGAL readout.
Big picture
This is not a fireworks headline today — it’s a progress report. But for investors in SLS, the next meaningful move could come when the company clears the 80-event mark and finally gets the REGAL data out into the wild. Until then, it’s all about patience, cash burn, and hoping the science eventually pays off.